英文業績のご案内

秘書 篠原由紀子へ E-mail (yukiko23@dokkyomed.ac.jp)でご連絡いただければ、
下記の文献をPDFファイルで送ります。（ご希望の論文の番号を記載してください）

1) **Yuki N**, Sato S, Yuasa T, Ito J, Miyatake T. 
   Computed tomographic findings of progressive supranuclear palsy compared with Parkinson's disease. 

2) **Yuki N**, Yoshino H, Sato S, Miyatake T. 
   Acute axonal polyneuropathy associated with anti-GM1 antibodies following *Campylobacter* enteritis. 

3) **Yuki N**, Sato S, Yoshino H, Miyatake T. 
   Axonal Guillain-Barré: reply. 

4) **Yuki N**, Yoshino H, Sato S, Miyatake T. 
   *Campylobacter* neuropathy: reply. 
   *Neurology* 1991;41:1327-1328.

5) **Yuki N**, Sato S, Itoh T, Miyatake T. 
   HLA-B35 and acute axonal polyneuropathy following *Campylobacter* infection. 

6) **Yuki N**, Sato S, Miyatake T, Sugiyama K, Katagiri T, Sasaki H. 
   Motoneuron-disease-like disorder after ganglioside therapy. 

7) **Yuki N**, Sato S, Miyatake T, Sugiyama K, Katagiri T, Sasaki H. 
   Motoneuron-disease-like disorder after ganglioside therapy: reply. 

8) **Yuki N**, Sato S, Inuzuka T, Miyatake T, Yoshino H. 
   Axonal degeneration in the Guillain-Barré syndrome and anti-GM1 ganglioside antibodies. 

9) **Yuki N**, Miyatake T, Ichihashi Y, Sato S, Katagiri T. 
   IgM anti-(GalNAc β1-4 Gal [3-2αNeuAc] β1-) antibody-mediated cytotoxicity in a patient with 
   amyotrophic lateral sclerosis-like disorder. 

    Acute relapsing sensory neuropathy associated with IgM antibody against B-series gangliosides containing a 
    GalNAcβ1-4(Gal3-2αNeuAc8-2αNeuAc) β1 configuration. 

11) **Yuki N**, Yoshino H, Sato S, Shinozawa K, Miyatake T. 
    Severe acute axonal form of Guillain-Barré syndrome associated with IgG anti-GD1a antibodies. 

12) Fujimoto S, **Yuki N**, Itoh T, Amako K. 
    Specific serotype of *Campylobacter jejuni* associated with Guillain-Barré syndrome. 


26) Ohsawa T, Miyatake T, **Yuki N**.
Anti-B-series ganglioside-recognizing autoantibodies in an acute sensory neuropathy patient cause cell
death of rat dorsal root ganglion neurons.

27) **Yuki N**.
Pathogenesis of axonal Guillain-Barré syndrome: hypothesis.

28) **Yuki N**, Taki T, Takahashi M, Saito K, Tai T, Miyatake T, Handa S.
Penner's serotype 4 of *Campylobacter jejuni* has a lipopolysaccharide that bears a GM1 ganglioside epitope
as well as one that bears a GD1a epitope.

29) Suzuki T, Obara Y, **Yuki N**.
Fisher's syndrome, anti-GQ1b antibody, and HLA-B39 antigen.

S, Miyatake T.
Motor neuron disease with multi-system involvement presenting as tetraparesis, ophthalmoplegia and
sensori-autonomic dysfunction.

31) Suzuki S, Kawaguchi M, Mizuno K, Takama K, **Yuki N**.
Immunochemical properties and ganglioside recognitions by *Campylobacter jejuni*- enterotoxin and cholera
toxin.

32) Sugita K, Ishii M, Takanashi J, Niimi H, **Yuki N**.
Guillain-Barré syndrome associated with IgM anti-GM1 antibody following *Campylobacter jejuni* enteritis.

33) **Yuki N**.
Fisher's syndrome: reply.

34) **Yuki N**, Taki T, Takahashi M, Saito K, Yoshino H, Tai T, Handa S, Miyatake T.
Molecular mimicry between GQ1b ganglioside and lipopolysaccharides of *Campylobacter jejuni* isolated
from patients with Fisher's syndrome.

35) Yamada M, **Yuki N**, Kamata T, Itoh Y, Miyatake T.
Expression of a blood group B antigen-related glycoepitope in human dorsal root ganglion cells.

36) **Yuki N**, Ichikawa H, Doi A.
Fisher syndrome after *Campylobacter jejuni* enteritis: human leukocyte antigen and the bacterial serotype.

37) **Yuki N**, Tsujino Y.
Familial Guillain-Barré syndrome subsequent to *Campylobacter jejuni* enteritis.

38) Takano H, **Yuki N**.
Fisher's syndrome associated with chickenpox and anti-GQ1b antibody.
39) **Yuki N.**, Handa S, Tai T, Takahashi M, Saito K, Tsujino Y, Taki T.
Ganglioside-like epitopes of lipopolysaccharides from *Campylobacter jejuni* (PEN 19) in three isolates from patients with Guillain-Barré syndrome.

40) **Yuki N.**
Successful plasmapheresis in Bickerstaff's brain stem encephalitis associated with anti-GQ1b antibody.

Atypical motor neuron disease with severe ophthalmoplegia: a report of two cases.

42) Kanzaki A, Yabuki S, **Yuki N.**
Bickerstaff's brainstem encephalitis associated with cytomegalovirus infection.

43) **Yuki N.**, Ichihashi Y, Taki T.
Subclass of IgG antibody to GM1 epitope-bearing lipopolysaccharide of *Campylobacter jejuni* in patients with Guillain-Barré syndrome.

44) Matsumoto A, Yoshino H, **Yuki N.**, Hara Y, Cashman NR, Handa S, Miyatake T.
Ganglioside characterization of a cell line displaying motor neuron-like phenotype: GM2 as a possible major ganglioside in motor neurons.

45) Kimura F, Ito T, **Yuki N.**, Nakajima H, Tanaka T, Shinoda K, Ohsawa N.
Longitudinal study of serum and cerebrospinal fluid (CSF) class-specific antibodies against *Campylobacter jejuni* and GM1 ganglioside in Guillain-Barré syndrome.

46) **Yuki N.**

47) **Yuki N.**, Takahashi M, Saito K, Yoshino H.
Traveler's diarrhea, *Campylobacter jejuni*, and acute motor axonal neuropathy.

48) **Yuki N.**
Acute paresis of extraocular muscles associated with IgG anti-GQ1b antibody.

49) **Yuki N.**, Miyagi F.
Possible mechanism of intravenous immunoglobulin treatment on anti-GM1 antibody-mediated neuropathies.

50) **Yuki N.**, Tagawa Y, Handa S.
Autoantibodies to peripheral nerve glycosphingolipids SPG, SLPG, and SGPG in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy.
51) Yokota T, Saito Y, **Yuki N**, Tanaka H.
Persistent increased threshold of electrical stimulation selective to motor nerve in multifocal motor neuropathy.

52) Yokota T, Inaba A, **Yuki N**, Ichikawa T, Tanaka H, Saito Y, Kanouchi T.
The F wave disappears due to impaired excitability of motor neurons or proximal axons in inflammatory demyelinating neuropathies.

53) **Yuki N**, Taki T, Handa S.
Antibody to GaINAc-GD1α and GaINAc-GM1b in Guillain-Barré syndrome subsequent to *Campylobacter jejuni* enteritis.

Cranial nerve enhancement on three-dimensional MRI in Miller Fisher syndrome.

55) **Yuki N**, Wakabayashi K, Yamada M, Seki K.
Overlap of Guillain-Barré syndrome and Bickerstaff's brainstem encephalitis.

56) **Yuki N**, Takahashi M, Tagawa Y, Kashiwase K, Tadokoro K, Saito K.
Association of *Campylobacter jejuni* serotype with anti-ganglioside antibody in Guillain-Barré syndrome and Fisher's syndrome.

57) Tagawa Y, Irie F, Hirabayashi Y, **Yuki N**.
Cholinergic neuron-specific ganglioside GQ1bα a possible target molecule for serum IgM antibodies in some patients with sensory ataxia.
*J Neuroimmunol* 1997;75:196-199.

58) **Yuki N**, Yamada M, Tagawa Y, Takahashi H, Handa S.
Pathogenesis of the neurotoxicity caused by anti-GD2 antibody therapy.

59) **Yuki N**, Ariga T.
Antibodies to fucogangliosides in neurological diseases.
*J Neurol Sci* 1997;150:81-84.

60) **Yuki N**, Tagawa Y, Irie F, Hirabayashi Y, Handa S.
Close association of Guillain-Barré syndrome with antibodies to minor monosialogangliosides GM1b and GM1α.
*J Neuroimmunol* 1997;74:30-34.

Fc portion of intravenous immunoglobulin suppresses the induction of experimental allergic neuritis.

Prominent sensory ataxia in Guillain-Barré syndrome associated with IgG anti-GD1b antibody.

63) Kikuchi M, Tagawa Y, Iwamoto H, Hoshino H, **Yuki N**.
Bickerstaff's brainstem encephalitis associated with IgG anti-GQ1b antibody subsequent to *Mycoplasma pneumoniae* infection: favorable response to immunoadsorption therapy.
64) Kikuchi M, Tagawa Y, Saotome S, Nonoyama T, Hoshino H, **Yuki N**.
Acute ophthalmoparesis associated with IgG anti-GQ1b antibody subsequent to *Streptococcus pyogenes* infection.

Gadolinium-enhancement of the spinal posterior roots in acute sensory ataxic neuropathy.
*Neurology* 1997;49:1470-1471.

66) **Yuki N**.
Molecular mimicry between gangliosides and lipopolysaccharides of *Campylobacter jejuni* isolated from patients with Guillain-Barré syndrome and Miller Fisher syndrome.

67) Uetakagaito M, Horikawa H, Yoshinaka H, Tagawa Y, **Yuki N**.
Two patients with acute Guillain-Barré syndrome treated with different apheresis methods.

68) Tagawa Y, **Yuki N**, Hirata K.
Ability to remove immunoglobulins and antiganglioside antibodies by double filtration plasmapheresis in Guillain-Barré syndrome: is it equivalent to plasma exchange?

69) Odaka M, **Yuki N**, Hirata K.
Comparison of the adsorption ability between tryptophan and modified tryptophan columns.

70) Taki T, **Yuki N**, Handa S.
Anti-ganglioside antibodies and molecular mechanism of development of Gullain-Barré syndrome.

71) **Yuki N**.
Anti-ganglioside antibody and neuropathy: review of our research.

72) Koga M, **Yuki N**, Takahashi M, Saito K, Hirata K.
Close association of IgA anti-ganglioside antibodies with antecedent *Campylobacter jejuni* infection in Guillain-Barré and Fisher’s syndromes.

73) **Yuki N**, Tagawa Y.
Acute cytomegalovirus infection and IgM anti-GM2 antibody.

74) **Yuki N**, Hirata K.
Preserved tendon reflexes in *Campylobacter* neuropathy.

75) Ohtsuka K, Nakamura Y, Tagawa Y, **Yuki N**.
Immunoadsorption therapy for Fisher syndrome associated with IgG anti-GQ1b antibody.

76) Kitazawa K, Tagawa Y, Honda A, **Yuki N**.
Guillain-Barré syndrome associated with IgG anti-GM1b antibody subsequent to *Mycoplasma pneumoniae* infection.
77) **Yuki N.,** Miyatake T.  
Guillain-Barré syndrome and Fisher’s syndrome following *Campylobacter jejuni* infection.  

78) **Yuki N.,** Hirata K.  
Postinfection sensory neuropathy associated with IgG anti-GD1b antibody.  

79) Tagawa Y, **Yuki N.,** Hirata K.  
Ability to remove immunoglobulins and anti-ganglioside antibodies by plasma exchange, double-filtration plasmapheresis and immunoadsorption.  

*N*-Glycolyneuraminic acid-containing GM1 is a new molecule for serum antibody in Guillain-Barré syndrome.  

81) Koga M, **Yuki N.,** Ariga T, Morimatsu M, Hirata K.  
Is IgG anti-GT1a antibody associated with pharyngeal-cervical-brachial weakness or oropharyngeal palsy in Guillain-Barré syndrome?  

82) Koga M, **Yuki N.,** Kashiwase K, Tadokoro K, Juji T, Hirata K.  
Guillain-Barré and Fisher’s syndromes subsequent to *Campylobacter jejuni* enteritis are associated with HLA-B54 and Cw1 independent of anti-ganglioside antibodies.  

83) Ohtsuka K, Nakamura Y, Hashimoto M, Tagawa Y, Takahashi M, Saito K, **Yuki N.**  
Fisher syndrome associated with IgG anti-GQ1b antibody following infection by a specific serotype of *Campylobacter jejuni*.  

84) Tsukaguchi M, Tagawa Y, Takeuchi H, **Yuki N.**  
IgM anti-GM2 antibody in a patient with Guillain-Barré syndrome subsequent to cytomegalovirus hepatitis, cross reacts with *N*-acetylgalactosaminyl GD1a.  
*J Neurol Neurosurg Psychiatry* 1998;65:407-408.

85) **Yuki N.,** Yamamoto T, Hirata K.  
Correlation between cytomegalovirus infection and IgM anti-MAG/SGPG antibody-associated neuropathy.  

86) Tanaka H, **Yuki N.,** Hirata K.  
Trochlear nerve enhancement on three-dimensional magnetic resonance imaging in Fisher syndrome.  

87) Kuwabara S, **Yuki N.,** Koga M, Hattori T, Matsuura D, Miyake M, Noda M.  
IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barré syndrome.  

88) **Yuki N.,** Tagawa Y, Hirata K.  
Minimal number of plasma exchanges needed to reduce immunoglobulin in Guillain-Barré syndrome.  
*Neurology* 1998;51:875-877.
89) **Yuki N**, Hirata K.
Fisher’s syndrome and group A streptococcal infection.

90) Kashihara K, Shiro Y, Koga M, **Yuki N**.
IgG anti-GT1a antibodies which do not cross react with GQ1b ganglioside in a pharyngeal-cervical-brachial variant of Guillain-Barré syndrome.
*J Neurol Neurosurg Psychiatry* 1998;65:799.

91) **Yuki N**, Koga M, Hirata K.
Isolated internal ophthalmoplegia associated with immunoglobulin G anti-GQ1b antibody.

Abducens nerve enhancement in acute ophthalmoparesis.

93) Tagawa Y, **Yuki N**, Hirata K.
Antiganglioside antibodies in various episodes in a patient with recurrent Guillain-Barré syndrome.
*J Neurol Neurosurg Psychiatry* 1998;65:952.

94) **Yuki N**.
Molecular mimicry in *Campylobacter jejuni* lipopolysaccharides and the development of Guillain-Barré syndrome: reply.

95) Kuwabara S, Asahina M, Koga M, Mori M, **Yuki N**, Hattori T.
Two patterns of clinical recovery in Guillain-Barré syndrome with IgG anti-GM1 antibody.

96) Koga M, **Yuki N**, Hirata K.
Oropharyngeal palsy in Guillain-Barré and Fisher’s syndromes is associated with muscle weakness in the neck and arm.

97) Koga M, **Yuki N**, Hirata K.
Antiganglioside antibody in patients with Guillain-Barré syndrome who show bulbar palsy as an initial symptom.

98) Kuwabara S, Asahina M, Nakajima M, Mori M, Fukutake T, Hattori T, **Yuki N**.
Special sensory ataxia in Miller Fisher syndrome detected by postural body sway analysis.

99) Hozumi A, **Yuki N**, Yamazaki K, Hirata K.
Facial diplegia with paraesthesias: facial nerve enhancement in three dimensional MRI.

100) Tagawa Y, **Yuki N**, Hirata K.
The 301 to 314 amino acid residue of β-tubulin is not a target epitope for serum IgM antibodies in chronic inflammatory demyelinating polyneuropathy.

101) Koga M, **Yuki N**, Takahashi M, Saito K, Hirata K.
Are *Campylobacter curvus* and *Campylobacter upsaliensis* antecedent infectious agents in Guillain-Barré and Fisher’s syndromes?
102) Koga M, Yuki N, Hirata K.
Subclass distribution and the secretory component of serum IgA anti-ganglioside antibodies in Guillain-Barré syndrome after Campylobacter jejuni enteritis.

103) Yuki N, Hirata K.
Relation between critical illness polyneuropathy and axonal Guillain-Barré syndrome.

104) Koga M, Yuki N, Ariga T, Hirata K.
Antibodies to GD3, GT3, and O-acetylated species in Guillain-Barré and Fisher’s syndromes: their association with cranial nerve dysfunction.

105) Yuki N, Ho TW, Tagawa Y, Koga M, Li CY, Koga M, Griffin JW.
Autoantibodies to GM1b and GalNAc-GD1a: relationship to Campylobacter jejuni infection and acute motor axonal neuropathy in China.

106) Odaka M, Yuki N, Hirata K.
Bilateral ballism in a patient with overlapping Fisher’s and Guillain-Barré syndromes.

107) Kuwabara S, Ogawara K, Koga M, Mori M, Hattori T, Yuki N.
Hyperreflexia in Guillain-Barré syndrome: relation with acute motor axonal neuropathy and anti-GM1 antibody.

108) Kuwabara S, Mori M, Ogawara K, Mizobuchi K, Hattori T, Koga M, Yuki N.
Axonal involvement at the common entrapment sites in Guillain-Barré syndrome with IgG anti-GM1 antibody.

109) Odaka M, Yuki N, Yoshino H, Kiso M, Ishida H, Hirata K.
Antibodies to GD1α and GQ1β in Guillain-Barré syndrome and the related disorders.

110) Yuki N.
Pathogenesis of Guillain-Barré and Miller Fisher syndromes subsequent to Campylobacter jejuni enteritis.

111) Mori M, Kuwabara S, Koga M, Asahina M, Ogawara K, Hattori T, Yuki N.
IgG anti-GQ1b positive acute ataxia without ophthalmoplegia.

112) Yuki N, Kuwabara S, Koga M, Hirata K.
Acute motor axonal neuropathy and acute motor-sensory axonal neuropathy share a common immunological profile.

113) Ang CW, Yuki N, Jacobs BC, Koga M, van Doorn PA, Schmitz PIM, van der Meché FGA.
Rapidly progressive, predominantly motor Guillain-Barré syndrome with anti-GalNAc-GD1a antibodies.

114) Yuki N.
Glycotope mimicry between human ganglioside and bacterial lipopolysaccharide induces autoimmune neuropathy.
115) Tagawa Y, Yuki N.  
Bickerstaff’s brainstem encephalitis associated with shingles.  

116) Kuwabara S, Ogawara K, Mizobuchi K, Koga M, Mori M, Hattori T, Yuki N.  
Isolated absence of F waves and proximal axonal dysfunction in Guillain-Barré syndrome with antiganglioside antibodies.  

117) Yamamoto T, Yuki N.  
No cytomegalovirus DNA in sera from patients with anti-MAG/SGPG antibody-associated neuropathy: reply.  

118) Yuki N, Hirata K.  
Distinctions between critical illness polyneuropathy and axonal Guillain-Barré syndrome: reply.  

119) Yuki N, Ang CW, Koga M, Jacobs BC, van Doorn PA, Hirata K, van der Meché FGA.  
Clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganglioside  

120) Yuki N, Odaka M, Hirata K.  
Bickerstaff’s brainstem encephalitis subsequent to _Campylobacter jejuni_ enteritis.  

121) Yuki N.  
Current cases in which epitope mimicry is considered a component cause of autoimmune disease: Guillain-Barré syndrome.  

122) Yuki N, Susuki K, Hirata K.  

123) Tagawa Y, Yuki N, Hirata K.  
Anti-SGPG antibody in CIDP: nosological position of IgM anti-MAG/SGPG antibody-associated neuropathy.  

124) Odaka M, Yuki N, Nobile-Orazio E, Carpo M, Hirata K.  
Antibodies to GM1(NeuGc) in Guillain-Barré syndrome after ganglioside therapy.  

125) Yuki N, Susuki K, Hirata K.  
Ataxic form of Guillain-Barré syndrome associated with anti-GD1b IgG antibody  

126) Yuki N, Koga M, Hirata K.  
Is _Campylobacter_ lipopolysaccharide bearing a GD3 epitope essential for the pathogenesis of Guillain-Barré syndrome?  

127) Susuki K, Yuki N, Muramatsu M, Hirata K.  
Unilateral ophthalmoparesis and limb ataxia associated with anti-GQ1b IgG antibody.  


142) Thomas C, **Yuki N**, Fertil B.
Influence of gangliosides or LPS-like gangliosides on the tumorcidal activity of adherent leukocytes.
*C R Acad Sci III* 2001;324:115-122.

143) Kuwabara S, Mori M, Ogawara K, Hattori T, **Yuki N**.
Indicators of rapid clinical recovery in Guillain-Barré syndrome.
*J Neurol Neurosurg Psychiatry* 2001;70:560-562.

144) Susuki K, **Yuki N**, Hirata K.
Fine specificity of anti-GQ1b IgG and clinical features.
Subject of an Editorial *Fine specificity of anti-GQ1b antibodies and clinical features* by Willison HJ in the same issue (*J Neurol Sci* 2001;185:5-9).

Comparative study of preceding *Campylobacter jejuni* infection in Guillain-Barré syndrome between Japan and The Netherlands.
*J Neurol Neurosurg Psychiatry* 2001;70:693-695.

146) Tagawa Y, **Yuki N**, Ohnishi A, Hirata K, Hosokawa S.
Parameters for monitoring treatment effects in CIDP with anti-MAG/SGPG IgM antibody.

147) Koga M, **Yuki N**, Hirata K.
Antecedent symptoms in Guillain-Barré syndrome: an important indicator for clinical and serological subgroups.

148) Mori M, Kuwabara S, Fukutake T, **Yuki N**, Hattori T.
Clinical features and prognosis of Miller Fisher syndrome.
*Neurology* 2001;56:1104-1106.

Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside.

150) Koga M, Tatsumoto M, **Yuki N**, Hirata K.
Range of cross reactivity of anti-GM1 IgG antibody in Guillain-Barré syndrome.

151) **Yuki N**, Susuki S, Odaka M, Hirata K.
Overlapping Guillain-Barré syndrome and Bickerstaff’s brainstem encephalitis associated with anti-GQ1b IgG antibody after herpes simplex virus infection.

152) Odaka M, **Yuki N**.
Anti-GQ1b IgG antibody syndrome: clinical and immunological features: reply.
*J Neurol Neurosurg Psychiatry* 2001;71:282-283.

153) **Yuki N**.
Infectious origins of, and molecular mimicry in, Guillain-Barré and Fisher syndromes.
154) Koga M, Yuki N, Tai T, Hirata K. 
Miller Fisher syndrome and Haemophilus influenzae infection. 
Neurology 2001;57:686-691.

Guillain-Barré syndrome mimicking botulism. 

156) Pan CL, Yuki N, Koga M, Chiang MC, Hsieh ST. 
Acute sensory ataxic neuropathy associated with monospecific anti-GD1b IgG antibody. 
Neurology 2001;57:1316-1318.

157) Yuki N, Koga M. 
Molecular mimicry in Guillain-Barré and Fisher syndromes. 

158) Ang CW, Koga M, Jacobs BC, Yuki N, van der Meché FGA, van Doorn PA. 
Differential immune response to gangliosides in Guillain-Barré syndrome patients from Japan and The Netherlands. 

159) Nishimoto Y, Koga M, Yuki N. 
Neck stiffness in two children with Guillain-Barré syndrome after Campylobacter jejuni infection. 

160) Kuwabara S, Yuki N. 
Electrophysiology in Guillain-Barré syndrome associated with anti-ganglioside antibodies: axonal degeneration and reversible physiologic conduction failure. 

161) Sakakibara Y, Mori M, Kuwabara S, Katayama K, Hattori T, Koga M, Yuki N. 
Unilateral cranial and phrenic nerve involvement in axonal Guillain-Barré syndrome. 

162) Migita M, Matsumoto T, Fujino O, Takaishi Y, Yuki N, Fukunaga Y. 
Two cases of influenza with impaired ocular movement. 

163) Odaka M, Yuki N. 
Clinical utility of antiganglioside antibody measurement in Guillain-Barré syndrome and related conditions. 

164) Arai M, Odaka M, Yuki N, Hirata K. 
A patient with overlapping Bickerstaff’s brainstem encephalitis, Miller Fisher syndrome and Guillain-Barré syndrome. 

165) Odaka M, Yuki N. 
Anti-GQ1b IgG antibody syndrome: clinical and immunological range: reply. 
J Neurol Neurosurg Psychiatry 2002;72:418-422.

166) Susuki K, Yuki N, Hirata K, Kuwabara S. 
Fine specificities of anti-LM1 IgG antibodies in Guillain-Barré syndrome. 

167) Yuki N, MD, Susuki K, Koga M, Nishimoto Y, Kamijo M. 
Myelin-derived glycolipids and animal models of Guillain-Barré syndrome: reply 


193) Odaka M, Yuki N, Yamada M, Koga M, Takemi T, Hirata K, Kuwabara S.
Bickerstaff’s brainstem encephalitis: clinical features of 62 cases and a subgroup associated with

194) Susuki K, Nishimoto Y, Yamada M, Baba M, Ueda S, Hirata K, Yuki N.
Acute motor axonal neuropathy rabbit model: immune attack on nerve root axons.

195) Koga M, Yuki N, Tsukada Y, Hirata K, Matsumoto Y.
CDR3 spectratyping analysis of the T cell receptor repertoire in Guillain-Barré and Fisher syndromes.
*J Neuroimmunol* 2003;141:112-117.

196) Yuki N, Saperstein DS.
Axonal Guillain-Barré syndrome subtypes: do we need more splitting?
*Neurology* 2003;61:598-599.

197) Matsuo M, Odaka M, Koga M, Tsuchiya K, Hamasaki Y, Yuki N.
Bickerstaff’s brainstem encephalitis associated with IgM antibodies to GM1b and GalNAc-GD1a.

198) Pan CL, Shun CT, Susuki K, Yuki N, Hsieh ST.
Pharyngeal-brachial palsy after cytomegalovirus colitis.

199) Mori I, Koga M, Hirata K, Yuki N.
Hand weakness onset Guillain-Barré syndrome.

200) Odaka M, Yuki N, Tatsumoto M, Tateno M, Hirata K.
Ataxic Guillain-Barré syndrome associated with anti-GM1b and anti-GalNAc-GD1a antibodies
*J Neurol* 2004;251:24-29.

201) Nishimoto Y, Odaka M, Hirata K, Yuki N.
Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid
examination.

202) Susuki K, Atsumi M, Koga M, Hirata K, Yuki N.
Acute facial diplegia and hyperreflexia: a Guillain-Barré syndrome variant.

203) Susuki K, Odaka M, Mori M, Hirata K, Yuki N.
Acute motor axonal neuropathy after *Mycoplasma* infection: evidence of molecular mimicry.
*Neurology* 2004;62:949-956 (selected for the ‘Highlights’ section in the issue)

204) Susuki K, Yuki N.
Effect of methylprednisolone in patients with Guillain-Barré syndrome.
*Lancet* 2004;363:1236-1237

205) Nagashima T, Koga M, Odaka M, Hirata K, Yuki N.
Clinical correlates of serum anti-GT1a IgG antibodies.
*J Neurol Sci* 2004;219:139-45
Carbohydrate mimicry between human ganglioside GM1 and *Campylobacter jejuni* lipooligosaccharide causes Guillain-Barré syndrome.  
*Proc Natl Acad Sci U S A* 2004;101:11404-11409

207) Nishimoto Y, Koga M, Kamijo M, Hirata K, **Yuki N.**  
Immunoglobulin improves a model of acute motor axonal neuropathy by preventing axonal degeneration.  
*Neurology* 2004;62:1939-1944

208) Kuwabara S, Ogawara K, Misawa S, Koga M, Mori M, Hiraga A, Kanesaka T, Hattori T, **Yuki N.**  
Does *Campylobacter jejuni* infection elicit "demyelinating" Guillain-Barré syndrome?  
*Neurology* 2004;63:529-533

209) Susuki K, Nishimoto Y, Koga M, Nagashima T, Mori I, Hirata K, **Yuki N.**  
Various immunization protocols for an acute motor axonal neuropathy rabbit model compared.  
*Neurosci Lett* 2004;368:63-67

210) Odaka M, Koga M, **Yuki N.**, Susuki K, Hirata K.  
Longitudinal changes of anti-ganglioside antibodies before and after Guillain-Barré syndrome onset subsequent to *Campylobacter jejuni* enteritis.  
*Review Series Pediatrics* 2004;2:22-23

211) Galassi G, Susuki K, Quaglino D, **Yuki N.**  
Post-infectious acute ataxia and facial diplegia associated with anti-GD1a IgG antibody.  
*Eur J Neurol* 2004;11:790-791

The crucial role of *Campylobacter jejuni* genes in anti-ganglioside antibody induction in the Guillain-Barré syndrome.  
*J Clin Invest* 2004;114:1659-1665

213) Takahashi M, Koga M, Yokoyama K, **Yuki N.**  
Epidemiology of *Campylobacter jejuni* isolated from patients with Guillain-Barré and Fisher syndromes in Japan.  

Overexpression of GD1a ganglioside sensitizes motor nerve terminals to anti-GD1a antibody-mediated injury in a model of acute motor axonal neuropathy.  
*J Neurosci* 2005;25:1620-1628 (selected for the ‘This Week in The Journal‘ section in the issue)

215) Kuwabara S, **Yuki N.**  
Does *Campylobacter jejuni* infection elicit "demyelinating" Guillain-Barré syndrome?: reply  
*Neurology* 2005;64:767

216) Hiraga A, Kuwabara S, Ogawara K, Misawa S, Kanesaka T, Koga M, **Yuki N.**, Hattori T, Mori M  
Patterns and serial changes in electrodiagnostic abnormalities of axonal Guillain-Barré syndrome.  
*Neurology* 2005;64:856-860.

Antecedent infections in Fisher syndrome: a common pathogenesis of molecular mimicry.  
*Neurology* 2005;64:1605-11